Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines
Abstract
:1. Introduction
2. Results
2.1. Cytokine and Chemokine Receptor Expressions in Primary Tumors and Metastasis-Originated Melanoma Cell Lines
2.2. Cytokine and Chemokine Receptor Expressions in Association with a BRAFV600E Mutation
2.3. Correlation of Invasive Behavior with Cytokine and Chemokine Receptor Expressions in Melanoma Cell Lines
3. Discussion
4. Materials and Methods
4.1. Melanoma Cell Lines
4.2. In Vitro Invasion Assay
4.3. Real-Time Quantitative PCR Analysis
4.4. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wang, X.; Lupardus, P.; Laporte, S.L.; Garcia, K.C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol 2009, 27, 29–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Signore, A.; Chianelli, M.; Bei, R.; Oyen, W.; Modesti, A. Targeting cytokine/chemokine receptors: A challenge for molecular nuclear medicine. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 149–156. [Google Scholar] [CrossRef] [PubMed]
- Oppenheim, J.J. Cytokines: Past, present, and future. Int. J. Hematol. 2001, 74, 3–8. [Google Scholar] [CrossRef] [PubMed]
- Spangler, J.B.; Moraga, I.; Mendoza, J.L.; Garcia, K.C. Insights into cytokine-receptor interactions from cytokine engineering. Annu. Rev. Immunol. 2015, 33, 139–167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11–22. [Google Scholar] [CrossRef]
- Do, H.T.T.; Lee, C.H.; Cho, J. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers 2020, 12, 287. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagarsheth, N.; Wicha, M.S.; Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 2017, 17, 559–572. [Google Scholar] [CrossRef] [Green Version]
- Raman, D.; Baugher, P.J.; Thu, Y.M.; Richmond, A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256, 137–165. [Google Scholar] [CrossRef] [Green Version]
- Kakinuma, T.; Hwang, S.T. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 2006, 79, 639–651. [Google Scholar] [CrossRef]
- Murakami, T.; Cardones, A.R.; Hwang, S.T. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 2004, 36, 71–78. [Google Scholar] [CrossRef]
- Li, X.J.; Liu, P.; Tian, W.W.; Li, Z.F.; Liu, B.G.; Sun, J.F. Mechanisms of CXCR7 induction in malignant melanoma development. Oncol. Lett. 2017, 14, 4106–4114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dunki-Jacobs, E.M.; Callender, G.G.; McMasters, K.M. Current management of melanoma. Curr. Probl. Surg. 2013, 50, 351–382. [Google Scholar] [CrossRef]
- Orgaz, J.L.; Sanz-Moreno, V. Emerging molecular targets in melanoma invasion and metastasis. Pigment. Cell Melanoma Res. 2013, 26, 39–57. [Google Scholar] [CrossRef] [PubMed]
- Paluncic, J.; Kovacevic, Z.; Jansson, P.J.; Kalinowski, D.; Merlot, A.M.; Huang, M.L.; Lok, H.C.; Sahni, S.; Lane, D.J.; Richardson, D.R. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim. Biophys. Acta 2016, 1863, 770–784. [Google Scholar] [CrossRef] [PubMed]
- Svedman, F.C.; Pillas, D.; Taylor, A.; Kaur, M.; Linder, R.; Hansson, J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe—A systematic review of the literature. Clin. Epidemiol. 2016, 8, 109–122. [Google Scholar] [CrossRef] [Green Version]
- Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275–292. [Google Scholar] [CrossRef] [Green Version]
- Jacquelot, N.; Duong, C.P.M.; Belz, G.T.; Zitvogel, L. Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. Front. Immunol. 2018, 9, 2480. [Google Scholar] [CrossRef]
- Samaniego, R.; Gutierrez-Gonzalez, A.; Gutierrez-Seijo, A.; Sanchez-Gregorio, S.; Garcia-Gimenez, J.; Mercader, E.; Marquez-Rodas, I.; Aviles, J.A.; Relloso, M.; Sanchez-Mateos, P. CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma. Cancer Immunol. Res. 2018, 6, 267–275. [Google Scholar] [CrossRef] [Green Version]
- Xiong, N.; Fu, Y.; Hu, S.; Xia, M.; Yang, J. CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell 2012, 3, 571–580. [Google Scholar] [CrossRef] [Green Version]
- Huang, R.; Rofstad, E.K. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J. Exp. Clin. Cancer Res. 2018, 37, 92. [Google Scholar] [CrossRef]
- Obenauf, A.C.; Massague, J. Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer 2015, 1, 76–91. [Google Scholar] [CrossRef] [Green Version]
- Babicki, S.; Arndt, D.; Marcu, A.; Liang, Y.; Grant, J.R.; Maciejewski, A.; Wishart, D.S. Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Res. 2016, 44, W147–W153. [Google Scholar] [CrossRef]
- Peinado, H.; Zhang, H.; Matei, I.R.; Costa-Silva, B.; Hoshino, A.; Rodrigues, G.; Psaila, B.; Kaplan, R.N.; Bromberg, J.F.; Kang, Y.; et al. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer 2017, 17, 302–317. [Google Scholar] [CrossRef] [PubMed]
- Massague, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. Nature 2016, 529, 298–306. [Google Scholar] [CrossRef]
- Timar, J.; Hegedus, B.; Raso, E. The role of lipid signaling in the progression of malignant melanoma. Cancer Metastasis Rev. 2018, 37, 245–255. [Google Scholar] [CrossRef]
- Lai, M.; Amato, R.; La Rocca, V.; Bilgin, M.; Freer, G.; Spezia, P.; Quaranta, P.; Piomelli, D.; Pistello, M. Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin. Sci Rep. 2021, 11, 11221. [Google Scholar] [CrossRef] [PubMed]
- Garandeau, D.; Noujarede, J.; Leclerc, J.; Imbert, C.; Garcia, V.; Bats, M.L.; Rambow, F.; Gilhodes, J.; Filleron, T.; Meyer, N.; et al. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Mol. Cancer Ther. 2019, 18, 289–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Da Cunha, B.R.; Domingos, C.; Stefanini, A.C.B.; Henrique, T.; Polachini, G.M.; Castelo-Branco, P.; Tajara, E.H. Cellular Interactions in the Tumor Microenvironment: The Role of Secretome. J. Cancer 2019, 10, 4574–4587. [Google Scholar] [CrossRef] [Green Version]
- Neagu, M.; Constantin, C.; Longo, C. Chemokines in the melanoma metastasis biomarkers portrait. J. Immunoass. Immunochem. 2015, 36, 559–566. [Google Scholar] [CrossRef]
- Borroni, E.M.; Mantovani, A.; Locati, M.; Bonecchi, R. Chemokine receptors intracellular trafficking. Pharmacol. Ther. 2010, 127, 1–8. [Google Scholar] [CrossRef]
- Duncan, L.M. The classification of cutaneous melanoma. Hematol. Oncol. Clin. N. Am. 2009, 23, 501–513. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.; Dowling, J.P.; Murray, W.K.; McArthur, G.A.; Thompson, J.F.; Wolfe, R.; Kelly, J.W. Rate of growth in melanomas: Characteristics and associations of rapidly growing melanomas. Arch. Dermatol. 2006, 142, 1551–1558. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lattanzi, M.; Lee, Y.; Simpson, D.; Moran, U.; Darvishian, F.; Kim, R.H.; Hernando, E.; Polsky, D.; Hanniford, D.; Shapiro, R.; et al. Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. J. Natl. Cancer Inst. 2019, 111, 180–188. [Google Scholar] [CrossRef] [PubMed]
- Warycha, M.A.; Christos, P.J.; Mazumdar, M.; Darvishian, F.; Shapiro, R.L.; Berman, R.S.; Pavlick, A.C.; Kopf, A.W.; Polsky, D.; Osman, I. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008, 113, 3341–3348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greenwald, H.S.; Friedman, E.B.; Osman, I. Superficial spreading and nodular melanoma are distinct biological entities: A challenge to the linear progression model. Melanoma Res. 2012, 22, 1–8. [Google Scholar] [CrossRef]
- Verfaillie, A.; Imrichova, H.; Atak, Z.K.; Dewaele, M.; Rambow, F.; Hulselmans, G.; Christiaens, V.; Svetlichnyy, D.; Luciani, F.; Van den Mooter, L.; et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun 2015, 6, 6683. [Google Scholar] [CrossRef] [Green Version]
- Qian, B.Z.; Li, J.; Zhang, H.; Kitamura, T.; Zhang, J.; Campion, L.R.; Kaiser, E.A.; Snyder, L.A.; Pollard, J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475, 222–225. [Google Scholar] [CrossRef] [Green Version]
- Korbecki, J.; Kojder, K.; Siminska, D.; Bohatyrewicz, R.; Gutowska, I.; Chlubek, D.; Baranowska-Bosiacka, I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int. J. Mol. Sci. 2020, 21, 8412. [Google Scholar] [CrossRef]
- Shen, S.; Zhang, Y.; Chen, K.G.; Luo, Y.L.; Wang, J. Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy. Mol. Pharm 2018, 15, 3642–3653. [Google Scholar] [CrossRef]
- Flores-Toro, J.A.; Luo, D.; Gopinath, A.; Sarkisian, M.R.; Campbell, J.J.; Charo, I.F.; Singh, R.; Schall, T.J.; Datta, M.; Jain, R.K.; et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc. Natl. Acad. Sci. USA 2020, 117, 1129–1138. [Google Scholar] [CrossRef]
- Teng, K.Y.; Han, J.; Zhang, X.; Hsu, S.H.; He, S.; Wani, N.A.; Barajas, J.M.; Snyder, L.A.; Frankel, W.L.; Caligiuri, M.A.; et al. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol. Cancer Ther. 2017, 16, 312–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trac, N.; Chen, L.Y.; Zhang, A.; Liao, C.P.; Poon, C.; Wang, J.; Ando, Y.; Joo, J.; Garri, C.; Shen, K.; et al. CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation. J. Control. Release 2021, 329, 614–623. [Google Scholar] [CrossRef] [PubMed]
- Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leonardi, G.C.; Falzone, L.; Salemi, R.; Zanghi, A.; Spandidos, D.A.; McCubrey, J.A.; Candido, S.; Libra, M. Cutaneous melanoma: From pathogenesis to therapy (Review). Int. J. Oncol. 2018, 52, 1071–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trojaniello, C.; Festino, L.; Vanella, V.; Ascierto, P.A. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Rev. Clin. Pharm. 2019, 12, 259–266. [Google Scholar] [CrossRef]
- Long, G.V.; Eroglu, Z.; Infante, J.; Patel, S.; Daud, A.; Johnson, D.B.; Gonzalez, R.; Kefford, R.; Hamid, O.; Schuchter, L.; et al. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined with Trametinib. J. Clin. Oncol. 2018, 36, 667–673. [Google Scholar] [CrossRef]
- Patel, H.; Yacoub, N.; Mishra, R.; White, A.; Long, Y.; Alanazi, S.; Garrett, J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 2020, 12, 482. [Google Scholar] [CrossRef] [Green Version]
- Ugurel, S.; Rohmel, J.; Ascierto, P.A.; Flaherty, K.T.; Grob, J.J.; Hauschild, A.; Larkin, J.; Long, G.V.; Lorigan, P.; McArthur, G.A.; et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017. Eur. J. Cancer 2017, 83, 247–257. [Google Scholar] [CrossRef] [Green Version]
- Lu, X.; Horner, J.W.; Paul, E.; Shang, X.; Troncoso, P.; Deng, P.; Jiang, S.; Chang, Q.; Spring, D.J.; Sharma, P.; et al. Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017, 545, 116. [Google Scholar] [CrossRef] [Green Version]
- Kemp, D.M.; Pidich, A.; Larijani, M.; Jonas, R.; Lash, E.; Sato, T.; Terai, M.; De Pizzol, M.; Allegretti, M.; Igoucheva, O.; et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget 2017, 8, 14428–14442. [Google Scholar] [CrossRef] [Green Version]
- Timar, J.; Kovalszky, I.; Paku, S.; Lapis, K.; Kopper, L. Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern. J. Cancer Res. Clin. Oncol. 1989, 115, 554–557. [Google Scholar] [CrossRef] [PubMed]
- Koroknai, V.; Szasz, I.; Hernandez-Vargas, H.; Fernandez-Jimenez, N.; Cuenin, C.; Herceg, Z.; Vizkeleti, L.; Adany, R.; Ecsedi, S.; Balazs, M. DNA hypermethylation is associated with invasive phenotype of malignant melanoma. Exp. Dermatol. 2020, 29, 39–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cell Line | Growth Phase a | Histologic Subtype b | Number of Invaded Cells/Field (Mean ± SD) c |
---|---|---|---|
WM793B | RGP/VGP | SSM | 125.5 ± 16.3 |
WM278 | VGP | NM | 86.0 ± 18.3 |
WM3211 | RGP/VGP | SSM | 76.5 ± 29.5 |
WM1366 | VGP | n.a. | 13.0 ± 1.4 |
WM983A | VGP | n.a. | 4.6 ± 2.6 |
WM3248 | VGP | n.a. | 0.0 ± 0.0 |
WM35 | RGP | SSM | 0.0 ± 0.0 |
WM1361 | VGP | SSM | 0.0 ± 0.0 |
WM902B | VGP | SSM | 0.0 ± 0.0 |
WM39 | VGP | NM | 0.0 ± 0.0 |
Primary Tumor Originated Melanoma Cell Lines a | ||||
Cell Line | Growth Phase b | Histologic Subtype c | BRAF Mutation Status d | NRAS Mutation Status e |
WM35 | RGP | SSM | V600E | wt |
WM793B | RGP/VGP | SSM | V600E | wt |
WM3211 | RGP/VGP | SSM | wt | wt |
WM1361 | VGP | SSM | wt | Q61L |
WM902B | VGP | SSM | V600E | wt |
WM39 | VGP | NM | V600E | wt |
WM278 p1 | VGP | NM | V600E | wt |
WM983A p2 | VGP | n.a. | V600E | wt |
WM1366 | VGP | n.a. | wt | Q61L |
WM3248 | VGP | n.a. | V600E | wt |
Melanoma Metastasis Originated Cell Lines | ||||
Cell Line | Location of Metastasis | BRAF Mutation STATUS | NRAS Mutation Status | |
WM1617 m1 | lymph node | V600E | wt | |
WM983B m2 | lymph node | V600E | wt | |
A2058 | lymph node | V600E | wt | |
HT168 ×1 | originated from A2058 | V600E | wt | |
HT168-M1 ×2 | originated from HT168 | V600E | wt | |
M24 | lymph node | wt | Q61R | |
WM165−1 | lymph node | V600D | wt | |
WM266−4 | lymph node | V600D | wt | |
WM239A | lymph node | V600D | wt |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Koroknai, V.; Szász, I.; Jámbor, K.; Balázs, M. Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines. Int. J. Mol. Sci. 2022, 23, 2644. https://doi.org/10.3390/ijms23052644
Koroknai V, Szász I, Jámbor K, Balázs M. Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines. International Journal of Molecular Sciences. 2022; 23(5):2644. https://doi.org/10.3390/ijms23052644
Chicago/Turabian StyleKoroknai, Viktoria, István Szász, Krisztina Jámbor, and Margit Balázs. 2022. "Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines" International Journal of Molecular Sciences 23, no. 5: 2644. https://doi.org/10.3390/ijms23052644